Cryo-Cell International, Inc. (CCEL) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cryo-Cell International, Inc. on May 6, 2026. The report addresses the status of the Company's common stock listing on the NYSE American LLC and the acceptance of a compliance plan to regain adherence to continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory listing status rather than financial performance data.
Material Changes and Listing Status
- Compliance Plan Accepted: On May 6, 2026, NYSE Regulation accepted the Company's plan to regain compliance with continued listing standards.
- Plan Period: The Company has been granted a plan period extending through September 9, 2027.
- Trading Status: Common stock will continue to be listed and traded on NYSE American during the plan period, subject to compliance with the plan's conditions.
Outlook, Risks, and Management Commentary
Management notes that there can be no assurance the Company will regain compliance by the September 9, 2027 deadline. If the Company fails to regain compliance or fails to make progress consistent with the accepted plan, NYSE American may initiate delisting proceedings. A press release detailing this announcement was issued on May 8, 2026.
Key Facts for Investor Verification
- Verify the specific financial or operational metrics required in the compliance plan to regain listing standards.
- Monitor the Company's progress reports to ensure they meet the milestones set by NYSE Regulation.
- Confirm the current trading status of CCEL on NYSE American to ensure no suspension has occurred.
- Review the full text of the compliance plan (referenced in the filing) to understand the specific conditions for avoiding delisting.